Delivery Order SPE2DB22D2006-SPE2DB25FW4BY
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for DESCOVY 200-25 mg tablets (30-count units) valued at $20,629.38 under a firm fixed-price contract. The award was made on September 3, 2025, with an ultimate completion date of September 4, 2025, and represents a non-set-aside competitive award. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor and will perform this delivery order from its corporate office location...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of DESCOVY 200-25 mg tablets (30-count units) with a ceiling value of $9,814.86. This is a firm fixed-price delivery order with an ultimate completion date of August 6, 2025, and represents a non-set-aside competitive award. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary...
- The Defense Logistics Agency awarded a delivery order valued at $36,331.88 to AmerisourceBergen Drug Corp for DESCOVY 200-25 mg tablets (quantity: 30 units) on August 12, 2025, with completion targeted for August 13, 2025. This firm fixed-price contract represents a non-set-aside, competitively awarded procurement of pharmaceutical supplies for federal medical needs. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of DESCOVY 200-25 mg tablets (30-count units) with a ceiling value of $12,630.26. This competitively awarded, firm fixed-price delivery order is set to be completed by July 31, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. The contract represents a continuation of AmerisourceBergen's substantial role as a critical...
- The Defense Logistics Agency awarded a $19,658.99 delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of DESCOVY 200-25 mg tablets in quantities of 30 units. This non-competitive, firm fixed-price delivery order is scheduled for completion by September 5, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $17,120.36 to AmerisourceBergen Drug Corp for DESCOVY 200-25 mg tablets (30-count units) on September 10, 2025, with completion targeted for September 11, 2025. This firm fixed price delivery order was awarded on a competitive basis with no set-aside designation. The contract performs in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters and primary distribution operations. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $3,745.07 to AmerisourceBergen Drug Corp for the supply of DESCOVY 200-25 mg tablets in quantities of 30 units. This is a firm fixed price delivery order with an ultimate completion date of August 25, 2025, awarded on August 22, 2025. The contract carries no set-aside designation and represents a competitively awarded transaction. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a $15,047.95 delivery order to AmerisourceBergen Drug Corp for DESCOVY 200-25 mg tablets (30-count units) on August 7, 2025, with an ultimate completion date of August 8, 2025. This is a firm fixed price, non-set-aside contract that leverages AmerisourceBergen's existing pharmaceutical supply infrastructure. The place of performance is the contractor's corporate office in Conshohocken, Pennsylvania. As a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of DESCOVY 200-25 mg tablets in quantities of 30 units, valued at $5,563.36. This is a firm fixed-price delivery order with an ultimate completion date of September 12, 2025, and represents a non-set-aside competitive award. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child delivery order under a...
- The Defense Logistics Agency (DLA) awarded a $26,109.77 delivery order to AmerisourceBergen Drug Corp for DESCOVY 200-25 mg tablets (30-count units) with an ultimate completion date of August 18, 2025. This competitively awarded, firm fixed-price contract represents a non-set-aside procurement and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical vendor for federal medical procurement, serves...
- SPE2DB22D2006Indefinite Delivery Contract
- SPE2DB22D2006-SPE2DB25FW4BYDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of DESCOVY 200-25 mg tablets in a quantity of 30 units, with a ceiling value of $4,347.55. This is a firm fixed price, competitively awarded delivery order with no set-aside designation and an ultimate completion date of September 10, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters and distribution operations for federal medical procurement. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 through December 2026. AmerisourceBergen serves as a prime pharmaceutical vendor for the Defense Logistics Agency's Medical Supply Chain, providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs and the Defense Health Agency. The company's substantial IDC enables flexible fulfillment of federal medical supply requirements across multiple therapeutic domains, positioning it as a critical vendor for the Department of Defense's pharmaceutical distribution network.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.3k | 9/9/25 |